AP3B1

Across TCGA pan-cancer cohorts, AP3B1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AP3B1 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher AP3B1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP3B1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

GBM, PDAC, and UCEC are the cancer types where AP3B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.652	0.778	.013	15	view →
PDAC	OS	Median	All	0.604	0.369	.007	14	view →
UCEC	DFS	Quartile	All	0.969	0.764	.023	8	view →
COAD	DFS	Tertile	All	1.000	0.925	.048	6	view →
HNSC	DFS	Median	IV	0.924	1.000	.037	1	view →
LUAD	DFS	Quartile	All	0.953	0.862	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AP3B1–GBM (DFS)

Open the GBM breakdown →